News from IMIM
The rare disease Sezary's Syndrome, a very aggressive cutaneous lymphoma of T-cell, has a new biomarker. Researchers from IMIM, in collaboration with IRB and IDIBAPS, have revealed the important role of the protein kinase TAK1 for diagnosing this disease.
This study, published in the journal Leukemia, might open the door to develop new treatments for this incurable disease. “The biomarker identifies and helps to diagnose and select the patients that can be treated with the inhibitors of the relevant pathways, a possibility that still needs additional studies” Espinosa, one of the researchers, explains. -Carlos Sierra/PRBB
IMIM website (In Spanish)
Gallardo F, Bertran J, López-Arribillaga E, González J, Menéndez S, Sánchez I, Colomo L, Iglesias M, Garrido M, Santamaría-Babí LF, Torres F, Pujol RM, Bigas A, Espinosa L. Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma. Leukemia. 2018 Feb 22. doi: 10.1038/s41375-018-0066-4